PRESS ROOM

ADAP Advocacy issued the following press releases:

---

ADAP Advocacy & Legacy Health Endowment Publish 340B White Paper

REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program

WASHINGTON, D.C. - ADAP Advocacy, today, in partnership with the California-based Legacy Health Endowment, released a thought-provoking white paper focusing on what’s at stake if the federal government fails to reform the 340B Drug Pricing Program, which is now the second largest federal prescription drug program in the United States, behind Medicare Part D. It reassesses the 340B framework through the patient experience, calling for improved oversight and accountability. The white paper, “REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program,” makes the case for the new 340B rebate model, highlighting the AIDS Drug Assistance Program as the Gold Standard among covered entities, which already largely operates under this model.

Download the Press Release:  PDF

---

Joint Statement on the Proposed Changes to Florida’s AIDS Drug Assistance Program

ADAP Advocacy and HealthHIV Conjoin Patient and Provider Concerns Threatening the Well-Being of Floridians Living with HIV/AIDS

WASHINGTON, D.C. - (March 3, 2026) – ADAP Advocacy and HealthHIV issued the following joint statement in response to the proposed changes to services for People Living with HIV/AIDS (PLWHA) as set forth in the Notice of Proposed Rule (NPR) #30517381, promulgated by the Florida Department of Health (DOH). ADAP Advocacy and HealthHIV have not previously submitted joint public comments; however, the magnitude and consequences of the proposed changes compel a unified response. The proposed changes to Florida Rules 64D-4.002, 64D-4.003, and 64D-4.007 necessitate a joint statement. Written comment was submitted to the state today.

Download the Press Release:  PDF

---

ADAP Advocacy Cautions Proposed Medicare Drug Price Controls Undermine Optimal Patient Care for Patients Living with HIV/AIDS

Centers for Medicare and Medicaid Services' Selection of the Highly Effective, Popular Antiretroviral Biktarvy Opens the Door to Unintended Consequences

WASHINGTON, D.C. - ADAP Advocacy today expressed deep concerns over the Centers for Medicare and Medicaid Services' (CMS) decision to select Biktarvy® (bictegravir, emtricitabine & tenofovir alafenamide), a highly effective and widely used HIV antiretroviral medication, as one of the 15 prescription drugs targeted for government price control under the Medicare Drug Price Negotiation Program for the Initial Price Applicability Year (IPAY) 2028. The decision could threaten the delicate service-delivery system for a health condition long rooted in exceptionalism—the idea that HIV/AIDS requires a response beyond "normal" health interventions.

Download the Press Release:  PDF

---

ADAP Advocacy Rescinds Three-Year Florida Travel Advisory

Ongoing Threats to Accessing Care and Treatment Facing Floridians Living with HIV/AIDS Warrants New Advocacy Strategy

WASHINGTON, D.C. - ADAP Advocacy today announced it has rescinded its travel advisory for people living with HIV/AIDS, which was issued in May 2023. The three-year-old travel advisory had applied to ADAP Advocacy board members, staff, consultants, and scholarship-funded patient advocates, and had also suspended hosting any patient advocacy events in Florida.

Download the Press Release:  PDF

---

ADAP Advocacy is an Organizational Partner of SYNC 2026

National Conference to be held March 18th-20th in Arlington, VA

WASHINGTON, D.C. - ADAP Advocacy today announced it is a proud organizational partner of the SYNChronicity 2026 (#SYNC2026) Annual National Conference for HIV, HCV, STIs, Drug User Health, and LGBTQ Health, to be held March 18th-20th in Arlington, Virginia.

Download the Press Release: PDF

---

ADAP Advocacy Urges Congress to Reject 340B Special Carveouts

Improving Patient Access and Affordability Depends on the Universal Implementation of the 340B Drug Pricing Program Rebate Model

WASHINGTON, D.C. - ADAP Advocacy cautions against "special" carveouts for Federally Qualified Health Centers (FQHCs), or any other covered entities, participating in the federal 340B Drug Pricing Program. The Trump Administration has joined a growing chorus calling for long-overdue reforms to the 340B Program, most notably by proposing a rebate model to replace the current upfront payments that drug manufacturers make to covered entities, which have led to increasing waste, fraud, and abuse.

Download the Press Release: PDF

---

ADAP Advocacy Urges Congress to Rein in Greedy American Health Insurance Companies

Major health insurers continue to rake in profits at the expense of patients, reporting revenue growth of 7.8% or greater, while patients struggle to afford ACA marketplace premium increases averaging 21.7% of Silver-level plans

WASHINGTON, D.C. - ADAP Advocacy insists that patients’ health is significantly more important than corporate profits for American health insurance companies. This message, however, seems not to have reached the ears of the four major health insurance companies, whose CEOs today testified before Congress before the House Committee on Energy and Commerce and the House Committee on Ways and Means.

Download the Press Release: PDF

---

Past Press Releases:
[2025] · [2024] · [2023] · [2022] · [2021] · [2020] · [2019] · [2018] · [2017] · [2016] · [2015] · [2014] · [2013] · [2012] · [2011] · [2010] · [2009]